부산대학교 도서관

Objective: In this study, the human absorbed dose of holmium-166 (166Ho)-pamidronate (PAM) as a potential agent for the management of multiple myeloma was estimated. Methods: 166Ho-PAM complex was prepared at optimized conditions and injected into the rats. The equivalent and effective absorbed doses to human organs after injection of the complex were estimated by radiation-absorbed dose assessment resource and methods proposed by Sparks et al based on rat data. The red marrow to other organ absorbed dose ratios were compared with these data for 166Ho-DOTMP, as the only clinically used 166Ho bone marrow ablative agent, and 166Ho-TTHMP. Results: The highest absorbed dose amounts are observed in the bone surface and bone marrow with 1.11 and 0.903 mGy MBq−1, respectively. Most other organs would receive approximately insignificant absorbed dose. While 166Ho-PAM demonstrated a higher red marrow to total body absorbed dose ratio than 166Ho-1,4,7,10-tetraazacyclo dodecane-1,4,7,10 tetra ethylene phosphonic acid (DOTMP) and 166Ho-triethylene tetramine hexa (methylene phosphonic acid) (TTHMP), the red marrow to most organ absorbed dose ratios for 166Ho-TTHMP and 166Ho-PAM are much higher than the ratios for 166Ho-DOTMP. Conclusion: The result showed that 166Ho-PAM has significant characteristics than 166Ho-DOTMP and therefore, this complex can be considered as a good agent for bone marrow ablative therapy. Advances in knowledge: In this work, two separate points have been investigated: (1) human absorbed dose of 166Ho-PAM, as a potential bone marrow ablative agent, has been estimated; and (2) the complex has been compared with 166Ho-DOTMP, as the only clinically used bone marrow ablative radiopharmaceutical, showing significant characteristics. [ABSTRACT FROM AUTHOR]